Sunday, April 29, 2012

Clanza CR




Generic Name: aceclofenac

Dosage Form: tablet, film coated

DESCRIPTION


White, oblong, film-coated tablet, engraved with "UT" on one side and "CL CR" on the other side.



INDICATIONS


Clanza CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism.



Dosage and Administration


Adults: The recommended dose is 200 mg daily, taken as one dose (every 24 hours).  However, the dose and dose frequency of Clanza CR can be modified under the supervison of physician or pharmacist.



CONTRAINDICATIONS


Patients with allergy to these drugs or other analogues (diclofenac). Patients with asthma. Like NSAIDS, acetylsalicylic acid and other drugs which inhibit prostagladin-synthesis may precipitate attacks of asthma, acute rhinitis or urticaria. Patients with active peptic ulcer.



CAUTIONS


Patients with symptoms indicative of gastro-intestinal disorders, with a history of gastroulceration.  Patients with severe hepatic impairment or cardiac or renal impairment.  Patients under the medication of diuretics.  Patients in recovery after surgical treatment.



ADVERSE REACTIONS


The majority of side effects observed have been reversible and of a minor nature and include gastro-intestinal disorders (dyspepsia, abdominal pain, nausea), rash, ruber, urticaria, symptoms of enuresis, headache, dizziness, and drowsiness.  To report suspected adverse reactions, call 1-800-FDA-1088.



GENERAL PRECAUTIONS


Patients suffering from dizziness, vertigo, or other central nervous system disorders while taking NSAIDS should refrain from driving or handling dangerous machinery.



DRUG INTERACTIONS


There has been no drug interactions reported, but close monitoring of patients on combination with lithium and digoxin, oral antidiabetic agents, anticoagulants, diuretics, and other analgesics.



USE IN PREGNANCY AND NURSING MOTHERS


Since there is no information on the safe use of Clanza CR during pregnancy and lactation, the use of Clanza CR should therefore be avoided in pregnancy and lactation.



USE IN CHILDREN


The dosage and indication is not established yet for children with less than 6 years old.



OVERDOSAGE


There are no human data available on the consequences of Clanza CR overdosage.  If overdosage is observed, therapeutic measures should be taken according to symptoms; supportive and symptomatic treatment should be given for complications such as hypotension, gastro-intestinal irritation, respiratory depression, and convulsions.



STORAGE


Preserve in tight containers.  Store at room temperature not exceeding 30oC.


SHELF LIFE


Three (3) years from manufacturing date.  Do not exceed the expiry date for use printed on the box.



PACKAGE


10 Blister Packs with 10 Tablets in each Blister Pack



Enter section text here



label test









CLANZA  CR
aceclofenac  tablet, film coated










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)65697-450
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Aceclofenac (Aceclofenac)Aceclofenac200 mg






































Inactive Ingredients
Ingredient NameStrength
Lactose Monohydrate 
Cellulose, Microcrystalline 
Sodium Carbonate 
Colloidal Silicon Dioxide 
Crospovidone 
Poloxamer 407 
Magnesium Stearate 
Alcohol 
Hypromellose 2208 (15000 MPA.S) 
Carbomer 941 
Hypromellose 2910 (6 MPA.S) 
Alcohol 
Methylene Chloride 
Hypromellose 2910 (5 MPA.S) 
Titanium Dioxide 
Ethylcelluloses 
Diethyl Phthalate 


















Product Characteristics
ColorwhiteScoreno score
ShapeOVAL (Film-coated white oblong tablet)Size15mm
FlavorImprint CodeUT;CR;CT
Contains      


















Packaging
#NDCPackage DescriptionMultilevel Packaging
165697-450-201 TABLET In 1 PACKETNone
265697-450-2210 BLISTER PACK In 1 CARTONcontains a BLISTER PACK (65697-450-21)
265697-450-2110 PACKET In 1 BLISTER PACKThis package is contained within the CARTON (65697-450-22)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Export only05/12/2011


Labeler - United Douglas Pharm., Inc. (001444350)

Registrant - United Douglas Pharm., Inc. (001444350)









Establishment
NameAddressID/FEIOperations
United Douglas Pharm., Inc.001444350pack, label









Establishment
NameAddressID/FEIOperations
Korea United Pharm Inc.688016534manufacture
Revised: 11/2011United Douglas Pharm., Inc.



No comments:

Post a Comment